<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03731286</url>
  </required_header>
  <id_info>
    <org_study_id>EB/180401/ENXTRA/EVRG</org_study_id>
    <nct_id>NCT03731286</nct_id>
  </id_info>
  <brief_title>A Long-term Safety and Efficacy of EnXtra (E-AG-01) in Healthy Adults</brief_title>
  <official_title>A Double-Blind Randomized, Double-dummy, Placebo-controlled, Parallel-Group Study of the Long-term Safety and Efficacy of EnXtra (E-AG-01) in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vedic Lifesciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vedic Lifesciences Pvt. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study has been proposed to investigate the long-term safety and efficacy of
      EnXtra in healthy adults habituated to caffeine.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 23, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ECG from baseline to end of the treatment.</measure>
    <time_frame>84 Days</time_frame>
    <description>ECG parameters including PR interval, QRS duration, QT interval and RR interval will be evaluated from baseline and end of the treatment</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Caffeine Dependence</condition>
  <arm_group>
    <arm_group_label>EnXtra</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EnXtra: 2 capsules to be taken twice daily after breakfast and evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Composite (EnXtra + Caffeine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Composite: 2 capsules to be taken twice daily after breakfast and evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microcellulose crystalline: 2 capsules to be taken twice daily after breakfast and evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EnXtra</intervention_name>
    <description>2 capsules</description>
    <arm_group_label>Composite (EnXtra + Caffeine)</arm_group_label>
    <arm_group_label>EnXtra</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EnXtra</intervention_name>
    <description>2 capsules</description>
    <arm_group_label>Composite (EnXtra + Caffeine)</arm_group_label>
    <other_name>Caffeine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Microcellulose crystalline</intervention_name>
    <description>2 capsules</description>
    <arm_group_label>EnXtra</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. History of regular caffeine consumption.

          2. Body mass index (BMI) of ≥18.5 and &lt;25.00 kg/m2.

          3. Fasting blood glucose &lt; 126 mg/dl

          4. Participants who are willing to complete all study procedures including study-related
             questionnaires and comply with study requirements.

          5. Participants who are willing to abstain from use of any nutritional supplement and
             herbal preparation 48 hrs prior to study visit.

        Exclusion Criteria:

          1. Participants unable to abstain from caffeine-containing products for 12 hours prior to
             the site visit.

          2. Known cases of type II Diabetes Mellitus.

          3. Participants with uncontrolled hypertension (≥140/90 mm Hg), with or without
             anti-hypertensive medication.

          4. Participants suffering from primary or secondary insomnia with/ without active
             treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vedic Lifesciences Pvt. Ltd</name>
      <address>
        <city>Mumbai</city>
        <state>Opp Infinity Mall</state>
        <zip>400053</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <last_update_submitted>October 9, 2019</last_update_submitted>
  <last_update_submitted_qc>October 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

